Assertio Therapeutics Inc (ASRT) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Assertio Therapeutics Inc (ASRT) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($5.71 Million) in capital expenditures ($180.00K). See Assertio Therapeutics Inc (ASRT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$5.71 Million
USD

Capital Expenditures

$180.00K
USD

Data as of

Dec 2023
Most recent filing

Assertio Therapeutics Inc Capital Reinvestment Ratio (2005–2023)

This chart tracks Assertio Therapeutics Inc's Capital Reinvestment Ratio across 14 annual periods.

Annual Capital Reinvestment Ratio for Assertio Therapeutics Inc (2005–2023)

Year-by-year Capital Reinvestment Ratio for Assertio Therapeutics Inc from 2005 to 2023. For live market cap and broader valuation context, see market value of Assertio Therapeutics Inc.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.01x $49.60 Million $628.00K ▲ +263.2%
2022 0.00x $78.60 Million $274.00K ▼ -63.7%
2021 0.01x $5.52 Million $53.00K ▼ -41.4%
2019 0.02x $90.47 Million $1.48 Million ▼ -78.5%
2018 0.08x $72.50 Million $5.51 Million ▲ +609.1%
2017 0.01x $62.17 Million $666.00K ▼ -75.5%
2016 0.04x $65.50 Million $2.86 Million ▼ -76.5%
2015 0.19x $143.89 Million $26.71 Million ▼ -7.7%
2013 0.20x $9.75 Million $1.96 Million ▲ +1561.4%
2011 0.01x $57.65 Million $698.00K ▼ -96.5%
2009 0.34x $1.84 Million $629.00K ▲ +346.2%
2008 0.08x $3.35 Million $257.00K ▲ +620.8%
2007 0.01x $14.66 Million $156.00K ▼ -61.2%
2005 0.03x $28.82 Million $791.25K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow